Systematix Corporate Services Invests ₹35,00,07,200 in Wholly Owned Subsidiary Through Rights Issue
Systematix Corporate Services Limited invested ₹35,00,07,200 in its wholly owned subsidiary Systematix Shares and Stocks (India) Limited through a rights issue, subscribing to 17,50,036 equity shares at ₹200 per share. The investment supports the subsidiary's working capital requirements as approved by shareholders in October 2024. The subsidiary operates as a SEBI-registered intermediary in capital markets with memberships across major exchanges and reported a turnover of ₹6,842.31 lakhs for FY 2024-25.

*this image is generated using AI for illustrative purposes only.
Systematix Corporate Services Limited has announced a substantial investment of ₹35,00,07,200 in its wholly owned subsidiary through a rights issue, demonstrating the company's commitment to strengthening its subsidiary operations. The investment was disclosed to stock exchanges on April 13, 2026, in compliance with SEBI listing regulations.
Investment Details
The company has subscribed to 17,50,036 equity shares of Systematix Shares and Stocks (India) Limited at an issue price of ₹200 per share, which includes a premium of ₹190 over the face value of ₹10 per share. This transaction represents a cash consideration investment in the wholly owned subsidiary.
| Parameter: | Details |
|---|---|
| Investment Amount: | ₹35,00,07,200 |
| Number of Shares: | 17,50,036 |
| Face Value: | ₹10 per share |
| Issue Price: | ₹200 per share |
| Premium: | ₹190 per share |
| Consideration Type: | Cash |
About the Subsidiary
Systematix Shares and Stocks (India) Limited is a SEBI-registered intermediary primarily engaged in broking business operations. The subsidiary holds memberships with major exchanges including BSE Limited, National Stock Exchange of India Limited, Multi Commodity Exchange of India Limited, and National Commodity and Derivatives Exchange. Additionally, the company operates as a SEBI-registered CDSL Depository Participant, Portfolio Manager, and Research Analyst.
Financial Performance
The subsidiary has demonstrated consistent business operations with varying turnover levels over the past three years. The company was incorporated on May 8, 1995, and operates exclusively within India's capital markets sector.
| Financial Year: | Turnover (₹ in Lakhs) |
|---|---|
| FY 2022-23: | 4,182.65 |
| FY 2023-24: | 7,342.19 |
| FY 2024-25: | 6,842.31 |
Strategic Rationale
This investment aligns with the objectives of the preferential issue approved by shareholders through a Special Resolution at the Extraordinary General Meeting held on October 14, 2024. The funds are designated for investment in subsidiaries, specifically for working capital requirements in the form of equity or quasi-equity investments.
Regulatory Compliance
The transaction qualifies as a related party transaction since Systematix Shares and Stocks (India) Limited is a wholly owned subsidiary. The company has confirmed that the transaction is conducted at arm's length, with promoter groups having no additional interest beyond their existing shareholding and directorship positions. No governmental or regulatory approvals are required for this acquisition, and the transaction will be completed within statutory timelines.
Following this investment, there will be no change in the percentage of shareholding, and Systematix Shares and Stocks (India) Limited will continue to remain a wholly owned subsidiary of Systematix Corporate Services Limited.
Historical Stock Returns for Systematix Corporate Services
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +4.99% | +1.88% | +15.74% | -54.37% | -47.75% | -47.75% |
How will this ₹350 crore capital infusion impact Systematix Shares and Stocks' competitive position in the increasingly crowded discount broking market?
What specific expansion plans or technology upgrades is the subsidiary likely to pursue with this substantial working capital boost?
Could this investment signal preparation for a potential IPO of the subsidiary, given the significant premium paid over face value?


































